Fitbit: From Fad to Future

Short-term target: $15 (130% upside)

What was once a piñata for short-sellers (since IPO) has transformed itself to one of the most underappreciated med-tech stories in the market with a balance sheet and brand equity that gives investors a tremendous investing opportunity.

For years, Wall Street has mentioned Fitbit and GoPro in the same breath – for some crazy reason. While their stock charts are similar and they both started as consumer products companies, that is where the similarities end.

Citron has done the analysis that NO ONE on Wall Street has taken the time to fully analyze and appreciate. Based on our work and the information that follows, we will explain why $FIT steps all the way up to $15/share in 2018 if not acquired first.